FI110234B - Menetelmä koostumuksen valmistamiseksi immuunivasteen aikaansaamiseksi antigeenille - Google Patents
Menetelmä koostumuksen valmistamiseksi immuunivasteen aikaansaamiseksi antigeenille Download PDFInfo
- Publication number
- FI110234B FI110234B FI934013A FI934013A FI110234B FI 110234 B FI110234 B FI 110234B FI 934013 A FI934013 A FI 934013A FI 934013 A FI934013 A FI 934013A FI 110234 B FI110234 B FI 110234B
- Authority
- FI
- Finland
- Prior art keywords
- antigen
- physiochemical
- cells
- protein
- forms
- Prior art date
Links
- 102000036639 antigens Human genes 0.000 title claims abstract description 106
- 108091007433 antigens Proteins 0.000 title claims abstract description 106
- 239000000427 antigen Substances 0.000 title claims abstract description 105
- 230000028993 immune response Effects 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 20
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 230000003612 virological effect Effects 0.000 claims abstract description 7
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 108700006640 OspA Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 229940099789 ospa protein Drugs 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 4
- 238000011260 co-administration Methods 0.000 description 19
- 230000004044 response Effects 0.000 description 11
- 101710105714 Outer surface protein A Proteins 0.000 description 9
- 241000700198 Cavia Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000589970 Spirochaetales Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000016173 B cell antigen processing and presentation Effects 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Enzymes And Modification Thereof (AREA)
- Radar Systems Or Details Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Jib Cranes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94317392A | 1992-09-14 | 1992-09-14 | |
| US94317392 | 1992-09-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI934013A0 FI934013A0 (fi) | 1993-09-14 |
| FI934013A FI934013A (fi) | 1994-03-15 |
| FI110234B true FI110234B (fi) | 2002-12-31 |
Family
ID=25479200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI934013A FI110234B (fi) | 1992-09-14 | 1993-09-14 | Menetelmä koostumuksen valmistamiseksi immuunivasteen aikaansaamiseksi antigeenille |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US5662909A (xx) |
| EP (1) | EP0588578B2 (xx) |
| JP (1) | JP2512689B2 (xx) |
| AT (1) | ATE187338T1 (xx) |
| AU (1) | AU677592B2 (xx) |
| CA (1) | CA2105629A1 (xx) |
| DE (1) | DE69327214T3 (xx) |
| DK (1) | DK0588578T4 (xx) |
| ES (1) | ES2141750T5 (xx) |
| FI (1) | FI110234B (xx) |
| GR (1) | GR3032543T3 (xx) |
| IL (2) | IL106968A (xx) |
| NO (1) | NO313178B1 (xx) |
| PT (1) | PT588578E (xx) |
| ZA (1) | ZA936629B (xx) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| ZA964896B (en) * | 1995-06-07 | 1997-01-08 | Connaught Lab | Expression of lipoproteins |
| US6251405B1 (en) * | 1995-06-07 | 2001-06-26 | Connaught Laboratories, Inc. | Immunological combination compositions and methods |
| WO2000039304A2 (en) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2596600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Modified hiv env polypeptides |
| US6602705B1 (en) * | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| US20050106137A1 (en) * | 2000-05-05 | 2005-05-19 | Stephen Grimes | Chimeric peptide immunogens |
| BRPI0116757B8 (pt) * | 2000-12-27 | 2021-05-25 | Corus Pharma Inc | composição, formulação e produto contendo aztreonam e uso do mesmo para aplicação via inalatória |
| US20030198621A1 (en) * | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
| US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| AU2002316578A1 (en) * | 2001-08-31 | 2003-03-18 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| US7425331B2 (en) * | 2002-04-10 | 2008-09-16 | Protalex, Inc. | Protein A methods of use |
| US7211258B2 (en) * | 2002-04-10 | 2007-05-01 | Protalex, Inc. | Protein A compositions and methods of use |
| US6814729B2 (en) | 2002-06-27 | 2004-11-09 | Technovision Gmbh | Laser vision correction apparatus and control method |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
| US4496538A (en) * | 1982-07-06 | 1985-01-29 | Connaught Laboratories, Inc. | Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine |
| GB8610983D0 (en) * | 1986-05-06 | 1986-06-11 | Connaught Lab | Enhancement of antigen immunogenicity |
| US4946676A (en) * | 1986-08-27 | 1990-08-07 | De Staat Der Nederlanden | Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide |
| EP0270295A3 (en) * | 1986-12-03 | 1989-08-02 | Connaught Laboratories Limited | Conjugate vaccine |
| DK425789A (da) * | 1988-08-31 | 1990-03-01 | Smithkline Beecham Corp | Vaccinale polypeptider |
| JPH0678245B2 (ja) * | 1989-07-04 | 1994-10-05 | 東興薬品工業株式会社 | 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤 |
| CA2084413A1 (en) * | 1990-06-15 | 1991-12-16 | Richard A. Flavell | Compositions and methods for the prevention and diagnosis of lyme disease |
| JPH06511154A (ja) * | 1991-10-18 | 1994-12-15 | コノート ラボラトリーズ インコーポレイテッド | 組換えＢｏｒｒｅｌｉａタンパクの製造法 |
-
1993
- 1993-09-07 CA CA002105629A patent/CA2105629A1/en not_active Abandoned
- 1993-09-08 ZA ZA936629A patent/ZA936629B/xx unknown
- 1993-09-08 AU AU46226/93A patent/AU677592B2/en not_active Ceased
- 1993-09-10 IL IL10696893A patent/IL106968A/en not_active IP Right Cessation
- 1993-09-13 DK DK93307185T patent/DK0588578T4/da active
- 1993-09-13 PT PT93307185T patent/PT588578E/pt unknown
- 1993-09-13 NO NO19933261A patent/NO313178B1/no unknown
- 1993-09-13 AT AT93307185T patent/ATE187338T1/de not_active IP Right Cessation
- 1993-09-13 DE DE69327214T patent/DE69327214T3/de not_active Expired - Fee Related
- 1993-09-13 ES ES93307185T patent/ES2141750T5/es not_active Expired - Lifetime
- 1993-09-13 EP EP93307185A patent/EP0588578B2/en not_active Expired - Lifetime
- 1993-09-14 FI FI934013A patent/FI110234B/fi not_active IP Right Cessation
- 1993-09-14 JP JP5229041A patent/JP2512689B2/ja not_active Expired - Lifetime
-
1995
- 1995-02-08 US US08/385,587 patent/US5662909A/en not_active Expired - Fee Related
- 1995-06-06 US US08/470,278 patent/US5837264A/en not_active Expired - Lifetime
-
1997
- 1997-02-18 US US08/801,152 patent/US5853736A/en not_active Expired - Fee Related
-
1998
- 1998-11-17 US US09/193,682 patent/US6024963A/en not_active Expired - Lifetime
-
1999
- 1999-05-23 IL IL13007599A patent/IL130075A0/xx unknown
-
2000
- 2000-02-02 GR GR20000400239T patent/GR3032543T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI934013A (fi) | 1994-03-15 |
| US5837264A (en) | 1998-11-17 |
| US5662909A (en) | 1997-09-02 |
| FI934013A0 (fi) | 1993-09-14 |
| GR3032543T3 (en) | 2000-05-31 |
| ES2141750T3 (es) | 2000-04-01 |
| ATE187338T1 (de) | 1999-12-15 |
| AU677592B2 (en) | 1997-05-01 |
| EP0588578B2 (en) | 2005-04-13 |
| JP2512689B2 (ja) | 1996-07-03 |
| NO933261D0 (no) | 1993-09-13 |
| DK0588578T4 (da) | 2005-07-25 |
| IL106968A0 (en) | 1993-12-28 |
| DE69327214T2 (de) | 2000-09-07 |
| EP0588578A1 (en) | 1994-03-23 |
| ZA936629B (en) | 1994-03-30 |
| DK0588578T3 (da) | 2000-03-27 |
| IL106968A (en) | 1999-10-28 |
| IL130075A0 (en) | 2000-02-29 |
| NO313178B1 (no) | 2002-08-26 |
| NO933261L (no) | 1994-03-15 |
| AU4622693A (en) | 1994-03-24 |
| EP0588578B1 (en) | 1999-12-08 |
| PT588578E (pt) | 2000-05-31 |
| CA2105629A1 (en) | 1994-03-15 |
| ES2141750T5 (es) | 2005-12-01 |
| JPH06192125A (ja) | 1994-07-12 |
| DE69327214T3 (de) | 2005-12-01 |
| US5853736A (en) | 1998-12-29 |
| US6024963A (en) | 2000-02-15 |
| DE69327214D1 (de) | 2000-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI110234B (fi) | Menetelmä koostumuksen valmistamiseksi immuunivasteen aikaansaamiseksi antigeenille | |
| US4950480A (en) | Enhancement of antigen immunogenicity | |
| Claassen et al. | The iscom structure as an immune enhancing moiety: experience with viral systems. | |
| US20050163808A1 (en) | Group A streptococcal polysaccharide immunogenic compositions and methods | |
| US5686078A (en) | Primary and secondary immunization with different physio-chemical forms of antigen | |
| JPH04230634A (ja) | 複合ワクチンのキヤリヤー分子としての、百日咳菌の繊維状赤血球凝集素 | |
| JPH04506662A (ja) | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー | |
| JP2000103745A (ja) | 処方物 | |
| Morein et al. | Functional aspects of iscoms | |
| RU2107493C1 (ru) | Липосомы, осуществляющие тимус-зависимую помощь "слабым" антигенам, используемым для приготовления вакцины | |
| Mora et al. | Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations | |
| Agrawal et al. | Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity | |
| Sjölander et al. | Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-ISCOM preparations. A comparison with other adjuvant systems | |
| EP0270295A2 (en) | Conjugate vaccine | |
| Decroix et al. | Mucosal Immunity Induced by Intramuscular Administration of Free Peptides In‐Line with PADRE: IgA Antibodies to the ELDKWA Epitope of HIV gp41 | |
| Li et al. | Conjugation of a Toll‐Like Receptor Agonist to Glycans of an HIV Native‐Like Envelope Trimer Preserves Neutralization Epitopes | |
| JP3051760B2 (ja) | ワクチンアジュバントとしての、ノイラミニダーゼおよびガラクトースオキシダーゼ | |
| EP0471954A2 (en) | Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide | |
| Teerlink et al. | Synergistic effect of detergents and aluminium phosphate on the humoral immune response to bacterial and viral membrane proteins | |
| Leibl et al. | Adjuvant/carrier activity of inactivated tick-borne encephalitis virus | |
| Lövgren-Bengtsson et al. | The ISCOM™ technology | |
| SVERREMARK et al. | Unresponsiveness following immunization with the T‐cell‐independent antigen dextran B512. Can it be abrogated? | |
| WO1991012819A1 (en) | Improved immunogenic compositions | |
| CA1327523C (en) | Antigen immunogenicity | |
| Balasa et al. | Immunotargeting of thyroglobulin on antigen presenting cells abrogates natural tolerance in the absence of adjuvant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: PHARMACIA & UPJOHN AKTIEBOLAG |
|
| HC | Name/ company changed in application |
Owner name: PHARMACIA & UPJOHN AKTIEBOLAG |
|
| MA | Patent expired |